DBV Technologies S.A.
DBV.PA$1.08B
Small CapEURONEXTBiotechnology🇺🇸North America117 employees
Drugs in Pipeline
7
Phase 3 Programs
5
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
DBV.PA News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
Viaskin Peanut 250 mcg
Peanut Allergy
Viaskin Peanut 250mcg
Peanut Allergy
DBV712
Allergy, Peanut
Part A Viaskin Peanut 250 mcg
Peanut Allergy
DBV712 250 mcg
Peanut Allergy
Viaskin Milk 150 mcg
Food Allergy
Viaskin Peanut 50 mcg
Peanut Allergy
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Viaskin Peanut 250 mcg | Phase 3 | Peanut Allergy | - | - |
Viaskin Peanut 250mcg | Phase 3 | Peanut Allergy | - | - |
DBV712 | Phase 3 | Allergy, Peanut | - | - |
Part A Viaskin Peanut 250 mcg | Phase 3 | Peanut Allergy | - | - |
DBV712 250 mcg | Phase 3 | Peanut Allergy | - | - |
Viaskin Milk 150 mcg | Phase 2 | Food Allergy | - | - |
Viaskin Peanut 50 mcg | Phase 2 | Peanut Allergy | - | - |
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply